Literature DB >> 19180207

Cervical human papillomavirus infection in accra, ghana.

Ab Domfeh1, Ek Wiredu, Aa Adjei, Pfk Ayeh-Kumi, Tk Adiku, Y Tettey, Rk Gyasi, Hb Armah.   

Abstract

BACKGROUND: This study was aimed at estimating the human papillomavirus (HPV) prevalence and its determinants among a sample of Ghanaian women.
DESIGN: Cross-sectional observational study.
SETTING: Gynaecology outpatient clinic of the Korle-Bu Teaching Hospital, Accra, Ghana; the largest tertiary care gynaecology outpatient clinic in Ghana. PARTICIPANTS: Convenient sample of 75 consenting women visiting the clinic.
METHODS: Information was obtained through personal interviews using structured questionnaire, Pap smears obtained, and laboratory testing of cervical exfoliated cells was performed. HPV DNA was detected using a GP5+/6+ polymerase chain reaction assay. These data were analyzed using both univariate and bivariate techniques.
RESULTS: The mean age of participants was 33.3 years (standard deviation, 9.2) and the percentage of lifetime monogamy was 21.3%. The crude HPV DNA prevalence was 10.7%. Unlike most populations studied so far, HPV prevalence was high not only among young women, but also in middle and old age. Independent HPV determinants were being illiterate (prevalence odds ratio [POR], 13.9; 95% confidence interval [95%CI], 1.9-100) and reporting more than three lifetime sexual partners (POR, 4.6; 95% CI, 1.0-22.2).
CONCLUSIONS: The study indicates a high crude prevalence of HPV in a largely polygamous Ghanaian population with a high crude prevalence in older age groups, which may be a distinctive feature of polygamous populations where HPV transmission continues into middle age and cervical cancer incidence is very high.

Entities:  

Keywords:  Ghana; HPV; PCR; Prevalence

Year:  2008        PMID: 19180207      PMCID: PMC2631263          DOI: 10.4314/gmj.v42i2.43596

Source DB:  PubMed          Journal:  Ghana Med J        ISSN: 0016-9560


  34 in total

1.  Human papillomavirus genotype prevalence in high-grade squamous intraepithelial lesions and colposcopically normal women from Zimbabwe.

Authors:  Patti E Gravitt; Anant M Kamath; Lynne Gaffikin; Z Michael Chirenje; Sharita Womack; Keerti V Shah
Journal:  Int J Cancer       Date:  2002-08-20       Impact factor: 7.396

2.  Human papillomavirus infection and cervical intraepithelial neoplasia in women with renal allografts.

Authors:  M I Alloub; B B Barr; K M McLaren; I W Smith; M H Bunney; G E Smart
Journal:  BMJ       Date:  1989-01-21

3.  HPV-based cervical cancer screening in a population at high risk for HIV infection.

Authors:  S D Womack; Z M Chirenje; L Gaffikin; P D Blumenthal; J A McGrath; T Chipato; S Ngwalle; M Munjoma; K V Shah
Journal:  Int J Cancer       Date:  2000-01-15       Impact factor: 7.396

4.  The interrelation of HIV, cervical human papillomavirus, and neoplasia among antenatal clinic attenders in Tanzania.

Authors:  P Mayaud; D K Gill; H A Weiss; E Uledi; L Kopwe; J Todd; G ka-Gina; H Grosskurth; R J Hayes; D C Mabey; C J Lacey
Journal:  Sex Transm Infect       Date:  2001-08       Impact factor: 3.519

Review 5.  Effective screening programmes for cervical cancer in low- and middle-income developing countries.

Authors:  R Sankaranarayanan; A M Budukh; R Rajkumar
Journal:  Bull World Health Organ       Date:  2001-11-01       Impact factor: 9.408

6.  Human papillomavirus genotypes in rural Mozambique.

Authors:  X Castellsagué; C Menéndez; M P Loscertales; J R Kornegay; F dos Santos; F X Gómez-Olivé; B Lloveras; N Abarca; N Vaz; A Barreto; F X Bosch; P Alonso
Journal:  Lancet       Date:  2001-10-27       Impact factor: 79.321

Review 7.  Human papillomavirus (HPV) infection in Southern Africa: prevalence, immunity, and vaccine prospects.

Authors:  Anna-Lise Williamson; Dianne Marais; Jo-Ann Passmore; Ed Rybicki
Journal:  IUBMB Life       Date:  2002 Apr-May       Impact factor: 3.885

8.  Human papillomavirus and risk factors for cervical cancer in Chennai, India: a case-control study.

Authors:  Silvia Franceschi; Thangarajan Rajkumar; Salvatore Vaccarella; Vendhan Gajalakshmi; Ajit Sharmila; Peter J F Snijders; Nubia Muñoz; Chris J L M Meijer; Rolando Herrero
Journal:  Int J Cancer       Date:  2003-10-20       Impact factor: 7.396

9.  Prevalence of papillomavirus infection in women in Ibadan, Nigeria: a population-based study.

Authors:  J O Thomas; R Herrero; A A Omigbodun; K Ojemakinde; I O Ajayi; A Fawole; O Oladepo; J S Smith; A Arslan; N Muñoz; P J F Snijders; C J L M Meijer; S Franceschi
Journal:  Br J Cancer       Date:  2004-02-09       Impact factor: 7.640

10.  Prevalence and determinants of HPV infection among Colombian women with normal cytology.

Authors:  M Molano; H Posso; E Weiderpass; A J C van den Brule; M Ronderos; S Franceschi; C J L M Meijer; A Arslan; N Munoz
Journal:  Br J Cancer       Date:  2002-07-29       Impact factor: 7.640

View more
  22 in total

1.  A qualitative assessment of the social cultural factors that influence cervical cancer screening behaviors and the health communication preferences of women in Kumasi, Ghana.

Authors:  Michelle S Williams
Journal:  J Cancer Educ       Date:  2014-09       Impact factor: 2.037

2.  Is routine human papillomavirus vaccination an option for ghana?

Authors:  A K Edwin
Journal:  Ghana Med J       Date:  2010-06

3.  Knowledge and beliefs about cervical cancer screening among men in Kumasi, Ghana.

Authors:  M S Williams; P Amoateng
Journal:  Ghana Med J       Date:  2012-09

4.  Prevalence, incidence and risk factors for anogenital warts in Sub Saharan Africa: a systematic review and meta analysis.

Authors:  Cecily Banura; Florence M Mirembe; Jackson Orem; Anthony K Mbonye; Simon Kasasa; Edward K Mbidde
Journal:  Infect Agent Cancer       Date:  2013-07-10       Impact factor: 2.965

5.  Estimation of the prevalence and distribution of HPV genotypes and identification of related risk factors among Turkish women.

Authors:  Mehmet Kulhan; Nur G Kulhan; Yasemin Seven; Umit A Nayki; Cenk Nayki; Nahit Ata; Pasa Ulug
Journal:  Contemp Oncol (Pozn)       Date:  2017-09-29

6.  Epidemiology of cervical human papillomavirus (HPV) infection and squamous intraepithelial lesions (SIL) among a cohort of HIV-infected and uninfected Ghanaian women.

Authors:  Dorcas Obiri-Yeboah; Patrick K Akakpo; Mohamed Mutocheluh; Emmanuel Adjei-Danso; Gloria Allornuvor; Daniel Amoako-Sakyi; Yaw Adu-Sarkodie; Philippe Mayaud
Journal:  BMC Cancer       Date:  2017-10-16       Impact factor: 4.430

7.  Recommendations for cervical cancer prevention and control in Ghana: public education and human papillomavirus vaccination.

Authors:  Yvonne Nartey; Philip Hill; Kwabena Amo-Antwi; Richard Asmah; Kofi Nyarko; Joel Yarney; Nelson Damale; Brian Cox
Journal:  Ghana Med J       Date:  2018-06

8.  Determining the prevalence of high-risk human papillomavirus infection using a novel cervical precancer screening approach in incarcerated women at the Nsawam Medium Security Prison, Ghana.

Authors:  Lawrence Kofi Acheampong; Kofi Effah; Joseph Emmanuel Amuah; Ethel Tekpor; Comfort Mawusi Wormenor; Isaac Gedzah; Seyram Kemawor; Ateba Cynthia Kachana; Peace Afi Danso; Nana Owusu Mensah Essel; Mabel Asomaning; Dominic Agyiri; Patrick Kafui Akakpo
Journal:  Ecancermedicalscience       Date:  2021-06-14

9.  Prevalence and predictors of Pap smear cervical epithelial cell abnormality among HIV-positive and negative women attending gynecological examination in cervical cancer screening center at Debre Markos referral hospital, East Gojjam, Northwest Ethiopia.

Authors:  Melkamu Getinet; Baye Gelaw; Abinet Sisay; Eiman A Mahmoud; Abate Assefa
Journal:  BMC Clin Pathol       Date:  2015-09-23

10.  Cancer incidence in Ghana, 2012: evidence from a population-based cancer registry.

Authors:  Dennis O Laryea; Baffour Awuah; Yaw A Amoako; E Osei-Bonsu; Joslin Dogbe; Rita Larsen-Reindorf; Daniel Ansong; Kwasi Yeboah-Awudzi; Joseph K Oppong; Thomas O Konney; Kwame O Boadu; Samuel B Nguah; Nicholas A Titiloye; Nicholas O Frimpong; Fred K Awittor; Iman K Martin
Journal:  BMC Cancer       Date:  2014-05-23       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.